Cross-sectional research design and relatively low HIV incidence, rather than blood exposures, explain the peripheral location of HIV cases within the sexual networks observed on Likoma Brewer et al. [1] argue that the location of HIV-infected individuals at the periphery of the sexual network observed on Likoma Island -rather than at its core -adds to the 'considerable evidence against penile-vaginal intercourse as the primary driver of HIV transmission in sub-Saharan Africa'. They suggest that 'unmeasured blood and sexual exposures', such as contaminated injections, are more relevant to the spread of HIV on the Island than the underlying network of heterosexual partnerships. We disagree with their interpretation of our results.
We highlighted several reasons why HIV cases may appear systematically less connected in the sexual network we describe [2] . First, our study is retrospective and only includes partnerships that took place within 3 years of the survey. Because this recall period is shorter than the duration of HIV infectivity, we omit some of the heterosexual relations having transmitted infection (i.e. those having taken place more than 3 years ago). The transmission network within which individuals were exposed to the risk of HIV is thus likely to be denser than the one we were able to reconstruct. Second, whereas the risk of HIV increases with age, acquisition of new sexual partners decreases with age. Younger respondents are more likely to be members of the bicomponents of the network but may actually have had fewer lifetime partners and have been exposed to the risk of HIV for a shorter period of time. Their risk of (prevalent) infection is thus reduced despite their having more central position in the network. Finally, once infected with HIV, individuals may reduce their number of partners and thus subsequently 'drift' into sparser network components. This might occur either because declining health (e.g. opportunistic infections, onset of AIDS) limits opportunities to meet new partners or because of the adoption of deliberate prevention strategies by infected individuals [3, 4] .
Brewer et al. [1] argue that no sexual risk variable in our study shows a 'meaningful association' with HIV infection. This is not the case: several variables related to sexual mixing patterns affect HIV risk. For example, residents of Likoma who reported having ever engaged in a sexual relationship with a resident of the mainland were almost twice as likely to be infected with HIV as other residents of the Island. We recently showed [5] that the risk of HIV infection among those with an external partner was further elevated when this partner was a temporary visitor to the Island rather than someone met during a trip to the mainland or an out-migrant. Furthermore, respondents who reported at least one mainland partner were also more likely to be included in small components of the network (because mainland partners and their partners were not traced during our study) [6] .
The interpretation of our findings by Brewer et al. [1] assumes that the incidence of HIV is high on Likoma. Indeed, studies on sexual networks show that, during epidemic phases (high incidence), cases of infection are generally located in the network cores [7, 8] whereas, during endemic phases (low incidence), cases of infection are found outside of such cores [7, 9, 10] . We recently conducted a follow-up to our study during which we approached all respondents previously contacted in 2006 and attempted to re-test them for HIV infection, using a protocol similar to the one described in [6] . Preliminary results of this follow-up indicate that the incidence of HIV on Likoma is low. Among the 293 respondents with negative test results in 2006 and for whom repeat HIV testing is currently available, only two new infections occurred during 439.5 person-years of follow-up (incidence rate ¼ 0.45 per 100). One of these incident cases occurred in the small components of the network, while the other occurred in the sparse 'branches' of the main component. Contrary to the assessment of Brewer et al. [1] , the peripheral location of HIV cases in the Likoma sexual network is thus consistent with results from the existing studies of sexual networks documenting contexts of endemic or declining sexually transmitted infections transmission.
We agree with Brewer et al. [1] that research designs that include partner tracing, sequencing of HIV isolates and comprehensive assessment of behavioral risk factors are needed to: (1) accurately measure the contribution of each mode of transmission to HIV epidemics and (2) design and prioritize interventions which are likely to produce effects on disease incidence. We, however, do not agree that the results of our study corroborate their opinion (e.g. [11] ) that contaminated injections and other blood exposures fuel HIV transmission in sub-Saharan Africa. Rather, it uncovers previously understudied patterns of sexual mixing that have important consequences for HIV spread in sub-Saharan settings.
Differences in proviral DNA load between HIV-1-infected and HIV-2-infected patients
Gueudin et al. [1] recently reported statistically significant lower levels of 'proviral' HIV-2 DNA in peripheral blood mononuclear cells (PBMC) of HIV-2-infected individuals compared with that found in HIV-1-infected individuals. They call into question numerous previous studies (including their own) that have found similar levels of HIV-1 and HIV-2 DNA in PBMC despite remarkably lower levels of plasma HIV-2 RNA than HIV-1 RNA in infected individuals [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . They base their findings on a novel real-time PCR assay that uses a 'coplasmid' standard that contains both long-terminal repeat (LTR) targets for HIV-1 and HIV-2 primers and probes. In a stratified analysis by CD4 cell counts in 40 HIV-1-infected and 42 HIV-2-infected antiretroviral naïve patients, they reported significantly higher levels of HIV-1 DNA compared with HIV-2 DNA in patients with CD4 cell counts greater than 500 cells/ml, between 500 and 300 cells/ml, and a nonsignificant trend for those lower than 300 cells/ml. Similar to previous studies, they found a significant increase in DNA levels for both HIV-1 and HIV-2 as CD4 cell counts decreased.
Unfortunately (and unlike some previous studies that found similar statistical differences in unadjusted, but not in adjusted analyses), they failed to adjust for CD4 cell count, and other potential factors (age, duration of infection, sex, etc.) affecting HIV PBMC DNA levels in multivariate analyses. Thus, it is possible that their observation is biased by different distributions of CD4 cell counts (or other confounders) between the HIV-1 and HIV-2 patients (with HIV-1 patients tending to have more rapid disease and lower CD4 cell counts in each strata). Also, despite differing levels of detection sensitivity for HIV-1 (10 copies/mg) and HIV-2 (20 copies/mg) in their new assay, and differing rates of detection of HIV-1 (37/40, 93%) and HIV-2 (31/42, 74%) in infected patients, they report that they set samples below the detection limit for both HIV-1 and HIV-2 at 10 copies/mg. It would have been reasonable to do a sensitivity analysis to determine how that 'arbitrary' cutoff might affect their results.
In addition, their assay actually measures total cellular HIV DNA (integrated, unintegrated, one and two LTR circles) and is not specific for 'proviral' (integrated) HIV: different levels of one and two LTR circles between HIV-1 and HIV-2 could, for example, confound measurements. A recent study by MacNeil et al. [12] reported that the total amount and percentage of integrated proviral HIV-1 and HIV-2 DNA are quite similar and not statistically different, and that lower levels of HIV-2 mRNA, and not proviral load levels, may help explain the markedly lower plasma HIV-2 RNA viral loads that have been universally observed.
Finally, Gueudin et al. [1] report that the HIV-2 plasma RNA viral loads were above the detection limit (100 copies/ml) in 12 of 42 (29%) patients. This percentage of patients with detectable HIV-2 plasma RNA viral loads is substantially lower than in other studies that have looked at HIV-2 plasma RNA levels in antiretroviral (ARV)-naïve patients (range 45-85%) [2, [7] [8] [9] 11, [13] [14] [15] [16] [17] [18] ], suggesting that their study population may not be representative of HIV-2 infection in general, and that their findings of low HIV-2 PBMC DNA levels may be a consequence of having the majority of their patients with low-plasma viral loads.
Using the same CD4 cell count cutoffs as reported by Gueudin et al. [1] we reanalyzed additional patients with HIV-1 (n ¼ 392) and HIV-2 (n ¼ 104) PBMC DNA levels that we previously reported from our Senegal Cohort using a modified Roche Amplicor DNA assay (Roche Amplicor Diagnostic systems Inc., Nutley, New Jersey, USA) with a limit of detection of 1 copy/mg [11] . In contrast, our data suggest that, at CD4 cell counts greater than 500 cells/ml, and between 300 and 500 cells/ml, the DNA levels are quite similar and, at low CD4 cell counts (<300 cells/ml), HIV-2 DNA levels are actually significantly higher compared with HIV-1 (Table 1) .
Overall, the preponderance of data suggests that levels of HIV-1 and HIV-2 DNA in PBMC are not the major reason for the markedly different levels of plasma virus and rates of disease progression found between these two types of HIV infection. Peginterferon monotherapy for the treatment of acute hepatitis C in HIV-coinfected patients
In recent years, in Western Europe, the incidence of acute hepatitis C virus (HCV) infection among HIV-infected men who have sex with men is increasing [1] [2] [3] . To date, only a small number of clinical trials have been performed and no evidence-based guidelines are available to guide the treatment of acute hepatitis C in HIV-coinfected patients. With much interest, we read the publication by Soriano et al. [4] on the updated recommendations from the HCV-HIV International Panel, published recently in this journal. After a short overview of acute hepatitis C in patients with chronic HIV infection, the authors recommended that these patients should be treated early with both pegylated interferon and ribavirin. They state that 'addition of ribavirin ensures maximal clearance of HCV'. As this recommendation in merely based on an expert opinion, we would like to argue this and advocate that these patients could be treated with pegylated interferon solely, for reasons mentioned below.
First, most available data about the treatment of acute hepatitis C come from trials performed in hepatitis C monoinfected patients. The first therapeutic trials in acute hepatitis C monoinfection, with varying interferon regimes and small numbers of included patients, showed a beneficial effect of treatment with responses varying between 25% and 91%. The first landmark trial by Jaeckel et al. [5] , treating 44 patients with interferon alfa-2b for a total of 24 weeks, resulted in a sustained viral response rate (SVR) of 98%. More recently, a few trials [6] [7] [8] [9] have shown that high response rates, varying between 72% and 94% can also be reached with peginterferon monotherapy. Up to now, there is no convincing evidence that addition of ribavirin to pegylated interferon will add any benefit [10] . Therefore, current guidelines for the treatment of acute hepatitis C monoinfection recommend peginterferon monotherapy instituted 12 weeks after seroconversion.
What about the evidence in HIV/HCV-coinfected patients? In recent years, three prospective trials have been published on the treatment of acute hepatitis C in HIV-coinfected patients [11] [12] [13] . Both Dominguez et al. [12] and Gilleece et al. [13] have treated their patients with the combination of peginterferon and ribavirin whereas Vogel et al. [13] compared peginterferon monotherapy with peginterferon/ribavirin combination therapy. The SVRs reached in these trials were comparable (59-71%). Moreover, no difference in SVR rate was seen between patients treated with peginterferon/ribavirin combination therapy versus peginterferon monotherapy [13] . Therefore, in our opinion, there is no firm evidence at the moment to support the addition of ribavirin to peginterferon in the treatment of acute HCV infection in HIV-coinfected patients.
A reason to withhold ribavirin is that it can be added to the treatment regimen in the later stages once chronic HCV is established, that is, in case of a nonresponse to early treatment or a relapse. Overall SVR rates in coinfected patients with acute HCV are substantially lower than in monoinfected patients (60 versus 90%). Therefore, a higher percentage of patients will fail treatment and will become chronic HCV carriers requiring re-treatment. Several trials in both HCV monoinfected and coinfected patients have shown that retreatment with peginterferon and ribavirin combination therapy in (peg)interferon experienced patients results in much lower SVR rates than in (peg)interferon naïve patients [14] [15] [16] [17] . Furthermore, it has been shown that, in chronic hepatitis C mono-infected patients, a less potent regime in the naïve chronic setting gives a higher chance of an acceptable SVR once re-treatment is necessary [18] . The addition of ribavirin in treating interferon nonresponders resulted in a higher SVR than re-treatment with interferon alone [19] [20] [21] . Moreover, HCV monoinfected patients who have a relapse after combination therapy need to be re-treated with higher doses of ribavirin and with prolonged courses of therapy [22, 23] . Therefore, withholding ribavirin can be advantageous in order to optimize the chances of achieving a SVR once the peginterferon monotherapy has failed and the patient becomes a nonresponder or a relapser.
Lastly, treatment of acute HCV infection in HIV coinfected patients with only peginterferon will result in less side effects (anaemia and thrombocytopenia), less interactions with antiretroviral agents and lower pill burden, resulting in a better compliance and higher chance to complete this therapy.
In conclusion, on the basis of these arguments, we believe that, at present, there is not enough evidence to firmly support combination therapy with peginterferon and ribavirin for the treatment of acute HCV infection in HIV positive patients. Withholding ribavirin in the acute treatment phase can maximize the chances of an acceptable SVR in case the patient is a nonresponder or has a hepatitis C relapse and has to be re-treated without diminishing the initial chances of a high SVR.
Severe rhabdomyolysis associated with raltegravir use Raltegravir, the first in a new class of antiretrovirals (ARVs) called HIV integrase inhibitors, was approved by the United States Food and Drug Administration (FDA) in October 2007. Approval was granted on the basis of results from two 24-week controlled trials conducted in 699 ARV-experienced HIV-infected patients with multidrug resistant virus who demonstrated reductions in plasma viral load (HIV RNA) [1] [2] [3] . Among the reported laboratory abnormalities were transient elevations in serum creatine kinase that did not necessitate drug interruption, and elevations in serum creatinine (SCr) that were often associated with concomitant tenofovir use [4] . The FDA and the manufacturer recommend that raltegravir be used with caution in individuals at increased risk for muscle problems, and they listed renal failure as a potential but uncommon adverse event [3, 5] .
Case report
We report the case of a 46-year-old African-American male with multidrug resistant HIV, first diagnosed in 1996, who experienced severe rhabdomyolysis while receiving a raltegravir-containing highly active antiretroviral therapy (HAART) regimen. This is the first reported case of severe rhabdomyolysis associated with raltegravir use. It became clinically apparent only after the frequent administration of i.v. fluid was discontinued. Although the FDA and manufacturer advise caution in patients deemed to be at increased risk for muscle problems, our patient had no identifiable risk factors when raltegravir was begun. He experienced acute worsening of his chronic renal insufficiency after raltegravir initiation and, unlike the majority of renal failure cases reported in clinical trials, was not receiving concomitant tenofovir. In our patient, it is not possible to determine the exact etiology of the acute renal failure or to discern the proportional contribution of raltegravir versus rhabdomyolysis. Clinicians should be alerted to the possibility of rhabdomyolysis in patients receiving raltegravir, even when discernable risk factors are not apparent, and should closely monitor creatine kinase and SCr values. Further study is warranted to determine the epidemiology of raltegravir-associated rhabdomyolysis. 
Cerebral thrombophlebitis as a paradoxical reaction in HIV-patients
The immune reconstitution inflammatory syndrome (IRIS) occurs frequently in patients infected with HIV and an opportunistic pathogen, usually a few weeks after the initiation of a combination antiretroviral therapy (cART) [1] . We report here two cases of HIV-infected patients who developed cerebral thrombophlebitis after the diagnosis and treatment of cryptococcal meningitidis, suggesting unusual presentation of IRIS.
Case 1
A 46-year-old HIV-1-infected African man was admitted on 13 May 2005 for right hemiparesia, diplopia, left VII and bilateral VI palsies. CD4 cell counts were 10 cells/ml and plasma viral load (pVL) was 1911 copies/ml despite cART with zidovudine, lamivudine and abacavir. His cerebrospinal fluid (CSF) showed 15 lymphocytes/ml, protein and glucose levels of 0.43 g/l and 2.4 mM/l, respectively. CSF direct examination and culture found Cryptococcus neoformans. Latex agglutination test for cryptococcal polysaccharide antigen was 68 enzyme immunoassay (EIA) in serum and 597 EIA in CSF. Cerebral magnetic resonance imaging (MRI) showed left frontal hemorrhagic lacuna and ischemic arteriolar lesions in lenticular nuclei. He was treated with intravenous amphotericin B and flucytosine, and high dose steroids. On 17 June 2005, while on fluconazole, steroids were interrupted and antiretroviral therapy was switched to emtricitabine, tenofovir and boosted atazanavir. On 26 July, he was hospitalized for headache, fever and visual acuity loss. CD4 cell count was 28 cells/ml and pVL was less than 50 copies/ml. CSF showed 14 cells/ml and cryptococcal yeasts, but culture was negative. The C. neoformans antigen was 45 EIA in blood and 12 EIA in CSF. Brain MRI showed thrombophlebitis of the superior sagittal and left transverse sinuses. Efficient anticoagulation and prednisone were initiated, with improvement of brain MRI 2 months later.
Case 2
On 19 November 2005, a 26-year-old African woman was hospitalized for photophobia, neck stiffness, right VI palsy revealing HIV infection and cryptococcal meningitis [20 cells/ml, 78% lymphocytes, positive cryptococcal antigen (1000 EIA) and C. neoformans in CSF]. CD4 cell count was 3 cells/ml and pVL was 200 000 copies/ml. She was treated with intravenous amphotericin B and flucytosine, then fluconazole. Eight days later, she presented a visual acuity loss. Brain MRI showed bilateral and symetric dilatation of the optical nerve sheathes and intracranial hypertension. Neurological signs disappeared after introduction of prednisone. On 17 January 2006, she started cART with emtricitabine, tenofovir and boosted atazanavir. On 6 March, she presented with blindness, confusion, neck stiffness, left VI palsy. CSF showed an opening pressure of 45 cmH 2 O, no cellularity, normoglycorachia, positive India ink coloration but negative culture for C. neoformans. MRI showed disappearance of venal flow in superior sagittal sinus and both transverse sinuses and intracranial hypertension. CD4 cell count was 9 cells/ml and pVL was 52 copies/ml. She received intravenous methylprednisolone, acetazolamide and curative anticoagulation. A ventriculoperitoneal derivation was performed without subsequent visual improvement.
Discussion
IRIS may develop in 30% of HIV-infected patients with cryptococcal infection [2] . The most common neurological presentations are a recurrent meningitis with negative fungal culture, multiple cerebral cryptococcoma, diffuse microabscesses, marked edema, or abnormal contrast media uptake in meninges [1, 3] . Cerebral venous occlusion has already been described in association with viral, bacterial or fungal infections and cancer, in HIVinfected patients [4] [5] and in non-HIV patients [6] [7] [8] [9] [10] [11] , but never in association with cryptococcosis. In one retrospective study, risk factors of cryptococcosisassociated IRIS in HIV-infected patients were previously unknown HIV infection, CD4 cell count lower than 7 cells/ml, fungemia and cART initiation within 2 months of cryptococcosis diagnosis [1] . Median CD4 cell counts at the time of IRIS were 215 cells/ml [1] . Our two patients maintained low CD4 cell counts below 50 cells/ml at the time of IRIS, and none of them had significant increase in their CD4 count. Nevertheless, cART might have beneficial immune effects mediated by mechanisms other than CD4 cell increment, as previously suggested [12, 13] , and low CD4 count does not rule out diagnosis of IRIS.
In our patients, the time from initial diagnosis of cryptococcosis to effective cARTwas 1 and 2 months and the time from initiation of an efficient cART to IRIS was 1 and 1.5 months, which were shorter than that reported in other cases [1, 14] . Both had cART introduced shortly after the diagnosis of cryptococcosis (one of them switched to a new cART due to bad compliance and virological failure of his previous treatment). Both also received high dosages of corticosteroids, but thrombophlebitis developed subsequently when therapy was decreased. Optimal treatment of patients at high risk of IRIS is still under discussion, with early or delayed introduction of cART and preventive long high dosage corticosteroids with potential adverse effects. Additional studies are thus needed.
Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin
A common adverse effect of interferon a therapy is neutropenia due to bone marrow suppression [1, 2] . Bacterial infections are infrequent in hepatitis C virus (HCV)-monoinfected patients, but their incidence in HIV-coinfected patients is poorly known [2] . The objective of this study was to determine the incidence and risk factors for bacterial infections among HIV/ HCV-coinfected patients enrolled in a randomized controlled trial comparing ribavirin in association with pegylated interferon or conventional interferon [3] .
The results of the ANRS HC02 RIBAVIC study have been reported elsewhere [3] . The main ineligibility criteria were decompensated cirrhosis; a CD4 cell count below 200 ml À1 , leukopenia (<3000 cells/ml); and neutropenia (<1500 cells/ml). We reviewed all events corresponding to bacterial infections that occurred during or less than 2 weeks after stopping treatment for HCV infection.
Episodes of infection were recorded if they were confirmed (positive culture or radiography) and if they required oral or parenteral antibiotic therapy. The investigators were advised to reduce the peginterferon a 2b dose from 1.5 to 1.0 or 0.5 mg/kg per week if the neutrophil count fell below 900 or 750 ml À1 , respectively, and to reduce the interferon a 2b dose from 3.0 to 1.5 million units three times per week if the neutrophil count fell below 750 ml À1 .
The primary endpoint was the time to onset of bacterial infections during treatment for HCV infection. Data were censored at the time of the last anti-HCV treatment intake. Univariate Cox proportional hazards models were used to identify factors associated with the primary endpoint. As the number of events was low, covariates with P-values below 0.05 in univariate analysis were confirmed by bootstrap analysis [4] . They were tested in a multivariate Cox proportional hazards model based on a backward elimination procedure. The final multivariate model was also confirmed by bootstrap analysis. All statistical tests were two-sided, with a type I error of 5%.
Eighteen bacterial infections occurred in 17 of the 383 patients who received at least one dose of study medication. There were two cases of pyelonephritis and one case of prostatitis (Escherichia coli), one case of diarrhea (Klebsiella oxytoca), two cases of septicemia (one due to Salmonella enterica and one to Staphycoccus aureus), one case of Streptococcus pneumoniae meningitis, eight lower respiratory tract infections (two in the same patient), one case of sinusitis and two cases of cellulitis.
Fifteen patients (88.2%) were men and the mean age was 39.9 AE 5.4 years. Fourteen were receiving antiretroviral therapy. At baseline, the mean CD4 lymphocyte count was 425 AE 205 cells/ml and plasma HIV RNA load was less than 400 copies/ml in eight patients.
At the onset of the bacterial infection, the median of polynuclear neutrophil (PNN) was 2448 ml À1 (range 820-19 700 ml À1 ). Two patients had neutropenia (820 and 1100 ml À1 ). Only one patient who developed an infection had neutropenia at baseline (770 ml À1 ). He developed sinusitis at week 12, despite the correction of neutropenia by granulocyte colony-stimulating factor therapy. During the course of HCV therapy, 54 out of 383 patients (14%) developed neutropenia less than 750 ml À1 , but only two presented bacterial infections. We found a 54 per 1000 patient-years incidence rate of bacterial infections during anti-HCV treatment. Independent risk factors for bacterial infections in our patients, whose HIV infection was well controlled, were only HCV-related: a longer history of HCV infection and a lower baseline prothrombin level. It is noteworthy that the duration of HCV infection correlates with the severity of fibrosis in HIV/HCV-coinfected patients and that advanced liver fibrosis is associated with increased risk of bacterial infection [5, 6] . Although cirrhosis was not more frequent in patients who had bacterial infections (n ¼ 4, 24%), low prothrombin levels are an established marker of advanced liver fibrosis. Others markers of liver fibrosis, low hemoglobin level and platelet count, were also associated with the risk of bacterial infection, but only in univariate analysis.
Neutropenia is not a risk factor for bacterial infection in HCV-monoinfected patients treated with interferon plus ribavirin [2, 7, 8] . Although interferon dose reductions for neutropenia were significantly more frequent in the peginterferon arm of our study (7% versus 2%, P ¼ 0.04), the type of interferon was not a risk factor [3, 8, 9] . In our study, only two patients among the 54 (3.7%) who developed neutropenia during the course of HCV therapy presented bacterial infection. Our results are in keeping with those of Cooper et al. [9] , who showed that neutrophil nadir did not predict infection risk.
In conclusion, factors independently associated with the risk of bacterial infection during interferon-ribavirin combination therapy in HIV/HCV-coinfected patients are related to the duration of HCV infection and to markers of liver fibrosis but, in contrast, not to neutropenia or characteristics of HIV infection, including CD4 cell count.
